Literature DB >> 3355608

beta-VLDL-induced alterations in growth potentiating activity produced by mononuclear phagocytes.

B M Schreiber1, B M Martin, W Hollander, C Franzblau.   

Abstract

This report describes the enhancement of growth potentiating activity produced by mononuclear phagocytes that were incubated with beta-migrating very low density lipoproteins (beta-VLDL). Conditioned media harvested from cultured human peripheral blood monocytes incubated in the presence or absence of the lipoprotein were evaluated for their ability to stimulate DNA synthesis ([3H]thymidine incorporation) of sparsely seeded quiescent BHK-21 (BHK) cells as well as neonatal rat aortic smooth muscle cells (NRSMC). Conditioned media from monocytes incubated in the presence of beta-VLDL enhanced [3H]thymidine incorporation into DNA of both BHK and NRSMC, when compared to conditioned media harvested from monocytes incubated in the absence of beta-VLDL. Studying NRSMC, this effect was evident using media collected from monocytes incubated with lipoprotein for 2 days; however, a longer incubation of monocytes plus lipoprotein was necessary to induce changes in growth potentiating activity for BHK cells. Likewise, the effect of beta-VLDL treatment of thioglycollate broth elicited BALB/c mouse peritoneal macrophages was evaluated. Conditioned media from lipoprotein-treated macrophages exhibited greater growth-stimulating activity for both BHK cells and NRSMC when compared to conditioned media from macrophages incubated in the absence of the lipoprotein. beta-VLDL did not affect viability of the mononuclear cells. These findings further implicate the involvement of the monocyte-derived foam cell in the development of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3355608     DOI: 10.1016/0021-9150(88)90290-0

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  7 in total

1.  Trafficking of endogenous smooth muscle cell cholesterol: a role for serum amyloid A and interleukin-1β.

Authors:  Lawrence G Pessolano; Christopher P Sullivan; Stephanie E Seidl; Celeste B Rich; Laura Liscum; Phillip J Stone; Jean D Sipe; Barbara M Schreiber
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-09-20       Impact factor: 8.311

2.  Apolipoprotein serum amyloid A down-regulates smooth-muscle cell lipid biosynthesis.

Authors:  B M Schreiber; M Veverbrants; R E Fine; J K Blusztajn; M Salmona; A Patel; J D Sipe
Journal:  Biochem J       Date:  1999-11-15       Impact factor: 3.857

3.  Superoxide production by macrophages stimulated in vivo with synthetic ether lipids.

Authors:  B M Schreiber; M D Layne; E J Modest
Journal:  Lipids       Date:  1994-04       Impact factor: 1.880

4.  Lysyl oxidase oxidizes cell membrane proteins and enhances the chemotactic response of vascular smooth muscle cells.

Authors:  Héctor A Lucero; Katya Ravid; Jessica L Grimsby; Celeste B Rich; Sandra J DiCamillo; Joni M Mäki; Johanna Myllyharju; Herbert M Kagan
Journal:  J Biol Chem       Date:  2008-06-27       Impact factor: 5.157

5.  High-mobility group box 1 contributes to lethality of endotoxemia in heme oxygenase-1-deficient mice.

Authors:  Rina Takamiya; Chi-Chih Hung; Sean R Hall; Koichi Fukunaga; Takashi Nagaishi; Toshitaka Maeno; Caroline Owen; Alvaro A Macias; Laura E Fredenburgh; Akitoshi Ishizaka; Richard S Blumberg; Rebecca M Baron; Mark A Perrella
Journal:  Am J Respir Cell Mol Biol       Date:  2008-12-18       Impact factor: 6.914

6.  Secretory phospholipase A2, group IIA is a novel serum amyloid A target gene: activation of smooth muscle cell expression by an interleukin-1 receptor-independent mechanism.

Authors:  Christopher P Sullivan; Stephanie E Seidl; Celeste B Rich; Michel Raymondjean; Barbara M Schreiber
Journal:  J Biol Chem       Date:  2009-10-22       Impact factor: 5.157

7.  Toll-like receptor 2 activation and serum amyloid A regulate smooth muscle cell extracellular matrix.

Authors:  Stephanie E Seidl; Lawrence G Pessolano; Christopher A Bishop; Michael Best; Celeste B Rich; Phillip J Stone; Barbara M Schreiber
Journal:  PLoS One       Date:  2017-03-03       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.